IN VIVO ANTIMALARIAL ACTIVITY OF METHANOLIC EXTRACT OF INNER BARK OF CORDIA AFRICANA AGAINST PLASMODIUM BERGHEI IN MICE by TESHOME, HANNA
 COLLEGE OF MEDICINE AND HEALTH SCIENCES 
SCHOOL OF PHARMACY 
DEPARTMENT OF PHARMACOLOGY 
 
IN VIVO ANTIMALARIAL ACTIVITY OF METHANOLIC EXTRACT OF INNER 
BARK OF CORDIA AFRICANA AGAINST PLASMODIUM BERGHEI IN MICE 
 
BY:  
HANNA TESHOME 
 
                                                         ADVISORS: 
                      ASSEFA BELAY (MSc, B. Pharm) 
                                 JIBRIL SEID (MSc, B. Pharm) 
 
A  THESIS SUBMITTED TO DEPARTMENT OF PHARMACOLOGY, SCHOOL OF 
PHARMACY, COLLEGE OF MEDICINE AND HEALTH SCIENCES, UNIVERSITY 
OF GONDAR, IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR  
MASTER DEGREE IN PHARMACOLOGY 
 
JUNE, 2015 
     GONDAR, ETHIOPIA 
I 
 
Summary 
Background:  Malaria is one of the major health problems in Sub-Saharan Africa including 
Ethiopia. One of the reasons attributed for this is the development and the emergence of 
multidrug resistant strains of the parasite to the current effective first-choice antimalarial drugs as 
well as resistant vectors to insecticides. A continued search for other effective, safe and cheap 
plant-based antimalarial agents thus becomes necessary in the face of these difficulties. 
Objective: The present study was aimed to evaluate the in vivo antimalarial activity of Cordia  
africana in mice.  
Methods: The inner bark extract of Cordia africana was extracted by methanol 80% using 
maceration method. The resulting extract was evaluated at doses of 100 mg/kg, 200 mg/kg, 400 
mg/kg using 4-day suppressive test.  
Results: The methanolic crude extract of Cordia africana showed 18.30, 24.84, and 31.37% (P < 
0.05) chemosuppression at the doses of 100, 200 and 400 mg/kg of extract, respectively as 
compared to negative control. The extract showed a significant weight loss at 400 mg/kg when 
compared with negative control but it did not change the body temperature of P. berghei infected 
mice. The extract was safe at the limit dose of 2,000 mg/kg in mice. Phenols, saponins and 
flavonoids were detected by the preliminary phytochemical screening. 
Conclusion: From this study it can be concluded that the inner bark extract of Cordia africana 
has antimalarial activity as seen in its ability to suppress P.berghei infection and this can be base 
for further studies to develop effective antimalarial agents. 
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1. Introduction 
1.1.  Etiology of malaria and its vectors 
Malaria is caused by a parasite called Plasmodium species. There are five Plasmodium 
species that cause human malaria. Plasmodium falciparum, Plasmodium vivax, Plasmodium 
malariae and Plasmodium ovale are human malaria species. Recently in Asia, Plasmodium 
knowlesi is the fifth major human malaria parasite, which is primarily a pathogen of monkeys 
(1, 2). 
The most prevalent and severe type of malaria is caused by P. falciparum. Secondly P. vivax 
is a common cause of malaria in Latin America, Asia and Oceania. P. malariae and P. ovale 
are much less common. In Ethiopia, malaria is contributed by both P. falciparum (64%) and 
P. vivax (36%) (3).  
Malaria is transmitted to humans through the bites of infected genus Anopheles mosquitoes. 
Among 400 different species of Anopheles mosquitoes thirty are important in malaria 
transmission. Anopheles arabiensis, Anopheles funestus, Anopheles gambiae, Anopheles 
melas, Anopheles merus, Anopheles moucheti and Anopheles nili have been reported as the 
dominant vector species for the transmission of malaria. Among these, An. gambiae and An. 
arabiensis are the most efficient vectors in malaria transmission especially in Ethiopia (4).  
1.2. Epidemiology of malaria 
1.2.1. Malaria globally 
Malaria is a major public-health problem in the world particularly in sub-Saharan African 
countries. It causes significant obstacle to socioeconomic development of the society in 
endemic countries (5). Globally, an estimated 3.2 billion people are at risk of being infected 
with malaria and developing disease, and 1.2 billion are at high risk according to world 
malaria report in 2014. According to 2013 malaria report 198 million cases and 584,000 
deaths of malaria occurred Worldwide. Malaria mortality rates have decreased by 47% and 
54% globally and in Africa, respectively, between 2000 and 2013 (6). 
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Africa especially SSA are the most affected countries in the world. 163 million cases of 
malaria have been occurred in Africa and most of them (78%) were in SSA. 528,000 malaria 
deaths have been estimated in Africa and 83% of these were children under five years in 
2013 (6). 
1.2.2. Malaria in Ethiopia 
Malaria is ranked as the leading communicable disease in Ethiopia. 75% of the country is 
malarious (7). Approximately 68% of the total population of 84.3 million lives in areas at 
significant risk of malaria. According to the federal ministry of health (FMOH), from 2010 to 
2011, malaria was the leading cause of outpatient visits, accounting for 15% of all visits, and 
health facility admissions, with 15% of all admissions. It is one of the top ten causes of 
inpatient deaths among children less than 5 years of age and adults (8). The most risky 
sections of the population are children under five years of age and pregnant women (9). 
Generally, areas below 2,000 meters above sea level in altitude are considered as malaria-
endemic (10).  
1.3.  Life cycle and pathogenesis of malaria 
The life cycles of all human malaria parasite species are similar. Infection begins when 
sporozoites, the infective stages, are injected by a mosquito and are carried around the body 
until they invade liver hepatocytes where they undergo a phase of asexual multiplication 
(exoerythrocytic schizogony) resulting in the production of many uninucleate merozoites. 
These merozoites flood out into the blood and invade red blood cells (RBCs) where they 
cinitiate a second phase of asexual multiplication (erythrocytic schizogony) resulting in the 
production of about 8 to 16 merozoites which invade new RBCs. This process is repeated 
almost indefinitely and is responsible for the disease, malaria (1). 
The Plasmodium parasite completes its life cycle through the mosquito when some of the 
merozoites that penetrate RBCs do not develop asexually into schizonts, but instead change 
into male and female sexual forms known as gametocytes. These circulate in the person’s 
bloodstream, awaiting the arrival of a blood-seeking female Anopheles mosquito. When a 
female mosquito bites an infected person, it sucks up gametocytes along with blood. Once in 
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the mosquito’s stomach, the gametocytes develop into sperm-like male gametes or large, 
egg-like female gametes. Fertilization produces an oocyst filled with infectious sporozoites. 
When the oocyst matures, it ruptures and the thread-like sporozoites migrate, by the 
thousands, to the mosquito’s salivary glands. The cycle starts over again when the mosquito 
bites its next victim (11).  
Malaria, especially P. falciparum malaria, can cause various pathologic complications 
involving various systems of the body. Cerebral malaria, acute renal failure, black water 
fever, hypoglycaemia, adult respiratory distress syndrome, disseminated intravascular 
coagulation, hypotension and shock are among the common manifestations of complicated 
malaria. Complicated malaria in pregnant women and in patients with HIV co-infection has 
increased morbidity and mortality (12). 
 
Figure 1. Life cycle of the malaria parasite. 
1.4. Clinical manifestations of malaria 
The symptoms first appear 10 to 16 days after the infectious mosquito bite (11). The first 
symptoms of malaria, common to all the different malaria species, are nonspecific and mimic 
a flu-like syndrome and the presentation may include headache, fever, shivering, arthralgia, 
vomiting, hemolytic anemia, jaundice, hemoglobinuria, retinal damage and convulsions. 
Although fever represents the cardinal feature, clinical findings in malaria are extremely 
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diverse and may range in severity from mild headache to serious complications leading to 
death, particularly in falciparum malaria (13). 
1.5. Diagnosis of malaria 
Malaria is diagnosed by the microscopic examination of blood films or by antigen-based 
rapid diagnostic tests (RDT) (14). Microscopy of stained thick and thin blood smears remains 
the gold standard for confirmation of diagnosis of malaria. High sensitivity, detection of 
malarial parasites at low densities and quantification of the parasite load are the advantages 
of microscopic examination.  It is possible to distinguish the various species of malaria 
parasite and their different stages (15). 
Commercially available RDTs are often more accurate than blood films at predicting the 
presence of malaria parasites, but they are unable to tell how many parasites are present (16). 
However, the specificities, sensitivities, numbers of false positives, numbers of false 
negatives and temperature tolerances of these tests vary considerably, illustrating the 
difficulties and challenges facing current RDTs (17).  
1.6. Prevention and control of malaria 
There are three types of measurements that can prevent malaria. These are personal 
protective, chemoprophylaxis and unit protective measures. None of the recommended 
interventions is 100% effective. Even in combination and when efficiently and consistently 
applied, malaria infection may still occur in high incidence (18). 
Over the past decade the use of LLINs, in combination with improved drug therapies, indoor 
residual spraying (IRS), and better health infrastructure has helped reduce malaria in many 
African countries. However, insecticide resistance in the vector is an evolving threat to these 
gains (19).  
In 2005, the Ethiopian government launched a massive expansion of the malaria prevention 
and control programme. The programme was aimed mainly at the reduction of malaria in 
populations living below 2,000 m above sea level. The massive scale-up of malaria control 
interventions, including case diagnosis and treatment, distribution of long-lasting insecticidal 
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nets (LLINs), and indoor residual spraying of households with insecticides have 
preferentially targeted malaria-endemic areas (10). 
1.7. Treatment of malaria 
Malaria is easily preventable and treatable if correct measures are taken which can include 
proper diagnostic tools, the availability of antimalarials and insecticides. Bed nets 
impregnated with insecticides and indoor residual spraying have eliminated malaria vectors 
from several settings (20). 
Once the diagnosis of malaria has been made, appropriate antimalarial treatment must be 
initiated immediately.Treatment should be guided by three main factors which include the 
nature of infecting Plasmodium species, the clinical status of the patient and the drug 
susceptibility of the infecting parasites as determined by the geographic area where the 
infection was acquired and the previous use of antimalarial medicines (21). 
Currently antimalarials are mostly targeting the asexual blood stage of the parasite’s life 
cycle. There are many other attractive targets that need to be investigated. The liver stages 
and the sexual stages will become more important as malaria control moves towards malaria 
elimination. Compounds active against the liver schizont would have a prophylactic effect 
and P. vivax elimination requires effectors against the dormant liver hypnozoites (22). 
The antimalarials in common use come from the following classes of compounds: the 
quinolines (chloroquine, quinine, mefloquine, amodiaquine, and primaquine), the antifolates 
(pyrimethamine, proguanil and sulfadoxine), the artemisinin derivatives (artemisinin, 
artesunate, artemether, arteether) and hydroxynaphthaquinones (atovaquine) (3). 
Quinine remains an important antimalarial drug almost 400 years after its effectiveness was 
first documented. However, its continued use is challenged by its poor tolerability, poor 
compliance with complex dosing regimens, and the availability of more efficacious 
antimalarial drugs (23).  
Currently artemisinin based combination therapy (ACT) is used as the first line treatment of 
uncomplicated falciparum malaria in over 100 countries and is the cornerstone of malaria 
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control and elimination programs in these areas. However, despite the high potency and rapid 
parasite killing action of artemisinin derivatives there is a high rate of recrudescence 
associated with artemisinin monotherapy and recrudescence is common even when ACT is 
used (24), whereas chloroquine is still commonly used for the treatment of non-falciparum 
species (25).   
1.8. Antimalarial drug resistance 
Malaria is a major public health problem mainly due to the development of resistance by the 
most lethal causative parasitic species, P. falciparum to the mainstay drugs like chloroquine 
(26). Chloroquine-resistant forms of P. falciparum malaria first appeared in Thailand in 
1957, then spread through South and Southeast Asia and by the 1970s were being se0en in 
SSA and South America. The rise in chloroquine resistance contributed to a worldwide 
increase in malaria-related mortality, particularly in SSA (27). 
Drug resistance in malaria has been defined as the "ability of a parasite strain to survive 
and/or multiply despite the administration and absorption of a drug given in doses equal to or 
higher than those usually recommended, but within the limits of tolerance of the subject" 
(28).   
ACT is used as the first line treatment of uncomplicated falciparum malaria in over 100 
countries and is the cornerstone of malaria control and elimination programs in these areas. 
However, despite the high potency and rapid parasite killing action of artemisinin derivatives 
there is a high rate of recrudescence associated with artemisinin monotherapy and 
recrudescence is common even when ACT is used (24).Therefore New drugs with unique 
structures and mechanism of action are urgently required to treat sensitive and drug-resistant 
strains of malaria (26). 
1.9. Plants as a source of antimalarials 
Traditional medicine uses crude extracts. Traditional medicines are used by ~ 80 % of 
Africans as a first response to ailment. Many of the traditional medicines have demonstrable 
antiplasmodial activities (29). Recent advances in antimalarial drug discovery from natural 
sources include plant extracts and compounds isolated from plants, bacteria, fungi and 
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marine organisms. These compounds offer new and novel scaffolds for development as 
antimalarials (30). 
Historically, compounds containing novel structure from natural origin represent a major 
source for the discovery and development of new drugs for several diseases (30). Natural 
compounds, mostly from plants, have been the mainstay of traditional medicine for 
thousands of years. They have also been the source of lead compounds for modern medicine. 
The advantage of natural compounds for the development of drugs derives from their innate 
affinity for biological receptors. Natural compounds have provided the best antimalarials 
known to date (29). Medicinal plants are a rich source of bioactive phytochemicals. These 
phytochemicals have an important role in preventing and treating various diseases including 
malaria (31).  
The success of the antimalarial drug quinine and the discovery of artemisinin, the most 
potent antimalarial drug, both from plant sources, has led to the study of plants as 
antimalarial agents. The ethnobotanical approach for the search of new and effective 
antimalarial agents and candidates from plant sources has proved to be more predictive and 
promising. Therefore, nature particularly plants used in traditional medicine are a potential 
source of new antimalarial drugs as they contain molecules with a great variety of structures 
and pharmacological activities (32). 
Resistance of malaria parasites to existing drugs complicates treatment, but an antimalarial 
vaccine that could protect against this disease is not yet available. It is therefore necessary to 
find new effective and affordable medicines. Medicinal plants could be a potential source of 
antimalarial agents (33). 
1.10. The experimental plant 
Cordia africana is grouped under the family of Boraginaceae and the genus of Cordia L. 
Boraginaceae Is a large family with more than 2,000 species in 100 to 145 genera. 19 genera 
and 62 species are found in Ethiopian (34).  
Cordia (L.) includes trees or shrubs. It has about 250 species in the tropical and subtropical 
regions of all continents. Around 10 species are found in Ethiopia (34).  
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Cordia africana (L.) is a small to medium sized tree, up to 18 m tall. Its bark is dark to pale 
brown, rough, fibrous, slash yellow to white turning green, grey or brown (34). 
  
Figure 2. Picture of Cordia africana. 
It is widespread in Sudan, South Africa, Angola, tropical Arabia, India and elsewhere in 
tropical botanic gardens. It is one of the most important timber trees in Ethiopia. It grows 
from 700 to 2,550 m altitude and It is common in Tigray, Gondar, Gojjam, Wello, Shewa, 
Arsi, Wollega, Illubabur, Keffa, Gamo Gofa, Sidamo, Bale and Harerge regions in Ethiopia 
(34). 
Traditionally, Cordia africana can be used for the treatment of different ailments such as 
respiratory diseases (35), abdominal pain (36), migraine, broken body, wounds, gastritis, 
constipation (37), malaria, diarrhea and dental problems (38).  
Besides being a source of medicine, Cordia africana has been utilized for various other 
purposes such as used for high quality furniture, doors, windows, cabinet making beehives, 
interior construction, mortars, and veneering (37).  
1.11. Statement of the problem  
Malaria is easily preventable and treatable if correct measures are taken (20). However, 
malaria recrudescence, increasing antimalarial drug and insecticide resistance, and the 
challenge of having effective vaccines are the major challenge for the success of treatment 
(5). Additionally, many antimalarial drugs in use today have high toxicity and low 
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therapeutic margin of indices that exposes patients’ additional harm and health expenditure 
(39). 
Malaria is still one of the greatest global public health problems especially in sub-Saharan 
Africa. It is estimated that it is directly responsible for the deaths of more than 1 million 
people each year the majority of which are due to cerebral malaria and other complications 
following infection with P. falciparum which is transmitted by female Anopheles mosquitoes 
and most of the deaths occur in Africa and in children under the age of 5 years (40). 
Many plant species are used in traditional medicines of malarious countries and a relatively 
few number of these have been investigated for evaluation of their antimalarial effect. Still 
lower is the number of those that have had the active natural compounds isolated and the 
toxicity determined (41). 
Most people living in developing countries including ethiopia are unable to afford the 
pharmaceutical drugs and those which are affordable are declining in their effectiveness due 
to the problem of drug resistance. So they heavily rely on traditional herbal medicinal plants 
which are not proven for their safety and efficacy with reliable scientific data. Therefore, 
there is a high demand to undertake anti-malarial activity evaluation and toxicological 
assessment on traditionally claimed medicinal plants and prepare standardized herbal 
preparations with a reasonable quality and affordable price (5). 
1.12. Significance of the study 
The emerging of drug resistance to conventional antimalarials, empirical treatment without 
proper laboratory investigation, challenge of having effective vaccines and adverse effects of 
the existing antimalarial drugs leads to urgent need of more effective, tolerable and 
affordable antimalarial drugs. 
Plants and their extracts have immense potential for treatment of malaria. However, there is a 
need for scientific validation, standardization and safety evaluation of traditionally used 
medicinal plants before they are recommended for treatment of malaria (42). Therefore, the 
list of traditionally used plants to control malaria must be backed by photochemical studies 
and scientific authentication to develop an appropriate phytomedicine.  
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Until recent times, the antimalarial activity and acute toxicity of Cordia africana, commonly 
used plant for the traditional treatment of malaria in Ethiopia, are not found in the literature. 
The present study, hence, provides information about its safety and efficacy in mice. 
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2. Objectives  
2.1. General objective 
  To evaluate the antimalarial effect of the crude methanol extract of inner bark of     
Cordial africana against P. berghei in mice. 
2.2. Specific objectives  
 To determine the antimalarial effects of crude methanol extract of inner bark of 
Cordial africana in mice infected with P. berghei using 4-day suppressive test. 
 To assess the acute toxicity of crude methanol extract of inner bark of Cordia 
africana in mice. 
 To perform preliminary phytochemical screening on crude methanol extract of inner 
bark of Cordial africana. 
 To assess the effect of the extract on the body weight and temperature of P. berghei 
infected mice.  
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3. Materials and methods 
3.1. Chemicals and instruments   
Chloroquine (Addis Pharmaceuticals Factory PLC. Ethiopia), methanol (Okhla Industrial, 
India), 10% giemsa(Sciencelab.com,inc, USA), trisodium citrate (Deluxe Scientific surgico 
Pvt. Ltd, India), 0.9% normal saline (Addis Pharmaceuticals Factory PLC, Ethiopia), 
Whatman filter paper (Whatman Ltd, England), microscopic slide frosted (Citoplus, China),  
electronic balance (ADP 720L, Adam Equipment Co. Ltd ), dry oven (250±10% volts, 
France), microscope, were used.  All chemicals and reagents were analytically graded and 
procured from certified suppliers. 
3.2. Collection, preparation, and identification of plant materials 
The fresh inner bark of Cordia africana was collected from Gondar town in February 2015. 
Then the plant material was air-dried at room temperature under shade and the size of the 
dried barks was reduced. After this it was packed in an air tight plastic bag until extraction 
done. A taxonomist from Addis Ababa University Addis Ababa Ethiopia identiﬁed the plant 
as Cordia africana lams. A specimen of the plant was deposited (with voucher no HT01) at 
the National Herbarium in the College of Natural Sciences at Addis Ababa University for 
future reference. 
3.3. Extraction of plant materials 
The dried plant material was weighed by electronic balance. A total of 350g dried barks were   
undergone metanolic extraction using maceration technique for 3 days with occasional 
stirring. The mixture was filtered with what man paper number one. The residue was re-
macerated twice for the same duration of days and then was filtered (43). 
The filtrates were collected and combined together. They were concentrated by oven (<40 
o
C.) .Finally, the dried extract was transferred to vial and was kept in desiccator until 
required for experiment.  
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3.4. Experimental animals 
Thirty Swiss albino mice, weighing 21-32 g and 6 to 8 weeks old, of either sex of inbred at 
the Animal House of the Department of Pharmacology, University of Gondar, were used. 
The animals were maintained under standard condition and were fed with a commercial 
rodent pellet diet and water ad libitum. All mice were acclimatized to the working 
environment one week prior to the experiments (44, 45). 
3.5. Parasites 
Chloroquine sensitive P. berghei was used for induction of malaria in experimental mice. 
Mice previously infected with P. berghei were used as donor. The donor P. berghei infected 
mice purchased from Aklilu Lemma Institute of Pathobiology, Addis Ababa University, 
Ethiopia. The parasites were subsequently maintained in the laboratory by serial passage via 
IP route on weekly basis (46, 47).  
3.6. Inoculum preparation 
Blood from a donor mouse was collected via cardiac puncture with a rising parasitaemia of 
about 30 to 40%. Zero point five percent (0.5%) trisodium citrate was added as anticoagulant 
and it was diluted with 0.9% normal saline. Each mouse was inoculated IP on day 0, with 0.2 
ml of this diluted blood containing approximately 1 x 10
7
 P. berghei infected erythrocytes 
(46). 
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3.7. Grouping and dosing of animals 
The mice were randomly divided into five groups of five mice each. The negative controls 
were treated with the vehicle (distilled water) used for reconstitution, whereas positive 
controls were treated with chloroquine 25mg/kg (the standard antimalarial drug). Three 
different doses of (100, 200, and 400) mg/kg of crude extract was administered to other 
groups (45). The standard drug (the positive control), the vehicle (the negative control) and 
the extracts were administered by oral route with the aid of an oral gavage. 
3.8. Pharmacological tests 
3.8.1. Acute toxicity test (Limit test) 
Female Swiss albino mice were used for acute oral toxicity study. Nulliparous and non-
pregnant female mice of 8 to 12 weeks of age were used. It was conducted as per the 
internationally accepted protocol drawn under OECD guidelines 425 (48).  
The mice were fasted for three hours and were weighed. The first animal was given a limit 
dose of 2,000 mg/kg of extract by oral gavage. The mouse was observed continuously for 
one hour after administration of the extract; intermittently for 4 hours, over a period of 24 
hours and for 14 days. The animal was observed for any gross behavioral changes such as 
loss of appetite, hair erection, lacrimation, tremors, convulsions, salivation, diarrhea, 
mortality and other signs of toxicity manifestation. As the mouse has survived at limit dose 
of 2,000 mg/Kg, four other mice were sequentially treated so that a total of five animals were 
tested (49).  
3.8.2. Four-day suppressive test 
The chemo suppressive test was done using standard four-day suppressive test against P. 
berghei infection in mice. The mice were randomly divided into five groups with five mice 
each. The three treatment groups were received at doses of 100, 200, and 400 mg/kg of the 
crude extracts. The control group was received 25 mg/kg of chloroquine (positive control 
group) and 0.5 ml/mice of distilled water (negative control group). Treatment was started 
three hours after infection and then continued for four consecutive days (46, 47).   
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On the fifth day, thin blood smears from the tail vein of each mouse were prepared on 
microscopic slides, fixed with absolute methanol and stained with 10% Geimsa solution at 
pH 7.2 for 15 minutes. The slides were taken out and dried with the room temperature. The 
number of parasitized RBC was examined under the microscope by a laboratory technician. 
The percentage suppression of parasitaemia was calculated for each test concentration by 
comparing the parasitaemia in infected controls with those received different concentrations 
of the test extract. Average percent parasitemia and percent parasitemia suppression were 
calculated by using the following formula (47, 50). 
% Parasitaemia = Number of parasite RBC x 100 
                    Total number of RBC count 
 
% Suppression = (X-Y) x 100 
                    X 
Where X is mean parasitemia of negative control group and Y is mean parasitemia of treated 
groups.  
3.8.3. Determination of body weight  
Body weight of each mouse was measured before infection (day 0) and on (day 4) using a 
sensitive digital weighing balance (49). 
3.8.4. Determination of temperature  
The rectal temperature of the mice was measured with a digital thermometer before infection, 
three hours after infection and then daily up to day 4 to see the effect of the extracts on body 
temperature (49). 
3.9. Preliminary phytochemical screening 
The methanolic extract of the inner bark of Cordia africana was subjected to preliminary 
phytochemical screening tests for various plant constituents using standard procedures. 
Identification was done by characteristic colour changes (43, 48, 52). The procedures 
followed to detect the phytochemicals were described in the annex part. 
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3.10. Statistical analysis 
Results were expressed as means + SEM and were analyzed using SPSS version 16. 
Comparisons were made between negative control, positive control and treatment groups of 
various doses using ANOVA following by post hoc test. At 95% confidence interval, P-
values less than 0.05 were considered as statistically significant.                                                                                                         
3.11. Ethical consideration 
The experimental animals were handled and cared in the experimental procedures according 
to the local ethical and internationally accepted laboratory animal use, care and welfare 
guidelines (44).  
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4. Results 
4.1. Percentage yield of extraction 
The nature of the extract and the actual and percentage yield of the methanolic extract of 
inner bark of Cordia africana were summarized in Table 1. 
Table 1: Percentage yield and physical description of the methanolic extract of the inner bark 
of Cordia africana.  
Extracting 
solvent 
Nature of the extract Color of the 
extract 
Actual Yield 
(g) 
Percentage 
Yield  
(%w/w)  
Methanol (80%) Hygroscopic 
powder 
Yellow  30  8.57 
4.2. Phytochemical screening  
Preliminary phytochemical screening for secondary metabolites was carried out on the crude 
methanolic extract of inner bark of Cordia africana. Flavonoids, phenols and saponins 
possibly present in this crude extract, shown in Table 2. Since the phytochemical screening 
tests used were preliminary, specific phytochemical tests are necessary for further 
confirmation of these results. 
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Table 2: Phytochemical screening test result of the crude methanolic extract of the inner bark 
of Cordia africana. 
Phytochemicals Remarks 
Anthraquinones  _ 
Terpinoids _ 
Saponins + 
Phenols + 
Flavonoides + 
Alkaloids _ 
Tannins _ 
Cardiac glycosides _ 
Sterols _ 
4.3. In vivo acute toxicity test  
The acute toxicity of the crude extract of the inner bark of Cordia africana showed that it did 
not cause any mortality within 24 hrs up to the limit dose of 2,000 mg/kg body weight of 
mice.  
4.4. Four-day suppressive test 
Four-day suppressive test of crude methanolic extract of the inner bark of Cordia africana 
significantly suppressed parasitemia in P. berghei infected mice. At 100, 200, and 400 mg/kg 
body of the crude extract, chemosuppressions were 18.30%, 24.84%, and 31.37%, 
respectively as shown in Table 3. 
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Table 3: Suppressive activity of crude methanolic extract of inner bark of Cordia africana 
against P. berghei in mice (Results are expressed as: Mean ± SEM; n = 5). 
Treatments Doses % Parasitemia % Suppression 
Negative control  0.5 ml 30.60±2.04 0.00
e3
 
CAIBE  100 mg/kg 25.00±2.83 18.30
e3
 
200 mg/kg 23.00±2.57 24.84
e3
 
400 mg/kg 21.00±1.95 31.37
e3a1
  
Positive control   25 mg/kg 3.00±1.00 90.20
a3b3c3d3
 
Where CAIBE=Cordia africana inner bark extract; a=as compared to negative control; b=as 
compared to 100 mg/kg; c=as compared to 200 mg/kg; d=as compared to 400 mg/kg; e=as 
compared to positive control; 1=p<0.05; 2=p<0.01 and 3=p<0.001.  
Unlike 100 and 200 mg/kg extract treated mice; 400 mg/kg extract treated mice showed a 
significant (P < 0.05) suppression when compared to negative control group. However, there 
were no significant (P > 0.05) parasitemia suppression differences among extract treated 
groups. The chemo-suppression induced by the standard drug, chloroquine, was 90.20% 
which was significant (P < 0.001) as compared to other treatment groups. 
4.5. Effects of the extract on body weights of mice 
The crude methanolic extract of inner bark of Cordia africana brought -0.38, -1.79
 
and -
2.41% weight loss activities at 100, 200 and 400 mg/kg while distilled water treated mice 
showed -0.85% as shown in Table 4. 
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Table 4: Effect of crude methanolic extract of the inner bark of Cordia africana on body 
weight of P. berghei infected mice (Results are expressed as: Mean ± SEM; n = 5). 
Treatments Doses Body Weight (gm) 
Pre-treatment Post-treatment % Wt Change 
Negative control 0.5 ml 29.32±1.30 29.07±1.34 -0.85
d1,e2
 
CAIBE  100 mg/kg 26.40±1.51 26.30±1.46 -0.38
d2
 
200 mg/kg 28.44±1.12 27.93±1.06 -1.79
e3
 
400 mg/kg 27.82±0.49 27.15±0.49 -2.41
a1,b2,e3
 
Positive control   25 mg/kg 27.62±0.79 27.95±0.84 1.19
a2,b1,c3,d3
 
Where CAIBE=Cordia africana Inner Bark Extract; a=as compared to negative control; 
b=as compared to 100 mg/kg; c=as compared to 200 mg/kg; d=as compared to 400 mg/kg; 
e=as compared to positive control; 1=p<0.05; 2=p<0.01; and 3=p<0.001.  
Unlike 100 and 200 mg/kg treated mice, 400 mg/kg of extract treated mice showed a 
significant (P < 0.05) body weight loss as compared to distilled water treated ones. There 
were clear differences (P < 0.05) in weight loss among extract treated groups. However, 
chloroquine treated mice showed a significant (P < 0.01) weight gain when compared to the 
distilled water treated ones. 
4.6. Effect of extract on body temperatures of mice 
The crude methanolic extract of inner bark of Cordia africana brought -0.30, 0.14, and 
0.17% change in body temperature of mice at 100, 200 and 400 mg/kg while the distilled 
water treated mice showed -0.52% change in body temperature. Even though the extract 
treated mice showed an increase in body temperature, they were insignificant (P > 0.05) 
compared to the negative and positive controls. But chloroquine treated mice showed 
significant (P < 0.05) body temperature increases as compared to negative controls as shown 
in Table 5.  
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Table 5: Effect of crude methanolic extract of the inner bark of Cordia africana on body 
temperature of P. berghei mice (Results are expressed as: Mean ± SEM; n = 5). 
Treatments Doses Body Temperature (C
o
) 
D0-Temp D4-Temp % Temp Change 
Negative control   0.5 ml 36.88±0.26 36.69±0.25 -0.52
e2
 
CAIBE  100 mg/kg 37.08±0.17 36.97±0.18 -0.30
e1
 
200 mg/kg 36.58±0.23 36.63±0.22 0.14 
400 mg/kg 35.28±0.98 35.34±1.02 0.17 
Positive control   25 mg/kg 36.54±0.30 37.12±0.31 1.59
a2,b1
 
Where CAIBE=Cordia africana Inner Bark Extract; D0-Temp is Body Temperature on day 
0; D4-Tmp is Body Temperature on day 4, a=as compared to negative control; b=as 
compared to 100 mg/kg; e=as compared to positive control; 1=p<0.05; and 2=p<0.01.  
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5. Discussion 
Plasmodium species that cause human disease are essentially unable to infect non-primate 
animal models. So, in vivo evaluation of antimalarial compounds typically begins with the 
use of rodent malaria parasites such as P. berghei, P. yoelii, P. chabaudi and P. vinckei. 
From these, P. berghei is used in predicting treatment outcomes of any suspected 
antimalarial agent due to its high sensitivity to chloroquine making it the appropriate parasite 
for the study of antimalarial activity of certain medicinal plants (46).  
Preliminary phytochemical screening tests of crude methanolic extract of the inner bark of 
Cordia africana possibly showed that the presence of flavonoids, phenols and saponins.  
These compounds are known to show antimalarial activity (52, 53), and therefore the current 
extract probably showed antimalarial activity due to the presence of such bioactive secondary 
metabolites.  
Phenols are broadly distributed in the plant kingdom and are the most abundant secondary 
metabolites of plants. Plant polyphenols have drawn increasing attention due to their potent 
antioxidant properties and their marked effects in the prevention of various oxidative stress 
associated diseases such as malaria (54). Similar results had been found on Parkia biglobosa 
at which phenolic compounds had major antimalarial activities (55). Hence, the parasitaemia 
suppression effect of the crude methanolic extract of the inner bark of Cordia africana may 
be attributed to the presence of these phenolic compounds. 
Methanol extract of the inner bark of Cordia africana was tested for its acute toxicity in 
mice. None of the test mouse died or showed signs of acute toxicity within 24 hours of 
treatment with the test extract. The extract was nontoxic to test mice, as they did not show 
signs of acute toxicity within 24 hours at the doses of 2000 mg/kg.  
The four-day suppressive test is a standard test commonly used for antimalarial screening, 
and the determination of percent inhibition of parasitaemia is the most reliable parameter 
(56). When a standard antimalarial drug is used in mice infected with P. berghei, it 
suppresses parasitemia significantly (p<0.05) (57). This is in agreement with the effects of 
chloroquine in this study which achieved 90.20% suppression of parasitaemia on a 4-day 
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suppressive test. The chemosuppressive effect of Cordia africana inner bark extract has 
shown the highest suppressive effect (31.37%) occurred at 400mg/kg/d which is comparable 
to the suppressive effect of other studies reported on Azadrachata indica (58) and Nauclea 
natifolia (59). The percentage of parasitaemia measured at 400mg/kg changed significantly 
(P<0.05) from those in the negative control group indicating that the extract has 
antiplasmodial activity and supports the traditional claim as antimalarial herbal remedy in 
Ethiopia. 
Body weight loss and fever are features of rodent malaria infections (60).The extract did not 
prevented significantly (p<0.05) body weight loss at tested doses when compared with the 
infected untreated control, this may be due to the extract may contain an agent which 
suppressed appetite. The result is similar to from reported on seed extract of Dodonaea 
angustifolia, which fails to prevent body weight loss (61).  
A decrease in the metabolic rate of infected mice occurs before death and is accompanied by 
a corresponding decrease in internal body temperature (62). Ideally, the rectal temperature 
decreases as parasite level escalates. Active compounds should prevent the rapid dropping of 
rectal temperature. The crude extract increased body temperature of mice, which might be 
constituents responsible for this effect were likely found in the extract. However, the increase 
in body temperature by extract is not significant when compared to distilled water treated 
mice. 
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6. Conclusion  
From this study it can be concluded that the methanol extract of inner bark of Cordia 
africana has antimalarial activity as seen in its ability to suppress p.berghei infection and this 
can be a base for further studies to develop effective antimalarial agents.   
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7. Suggestions for further work  
From this study, it can be suggested that: 
 The crude extract of the inner bark of Cordia africana should be fractionated to 
isolate, identify and elucidate the possible antiplasmodial compounds. 
 The subacute, chronic and cytotoxic potential of the plant should be studied to know 
better about the safety of the plant for traditional usage. 
 It would appropriate to study other biological activities of the plant claimed by 
traditional medicine. 
 It would also better to the study the effect of the plant on human malaria parasites. 
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9. Annexes  
The phytochemicals found in the crude methanol extract of inner bark of Cordial africana 
will be detected by the following standard preliminary phytochemical screening tests.  
Test for phenols 
1ml aqueous solution of the crude extract will be treated with few drops of 10% ethanolic 
ferric chloride and a color change to dark blue is affirmative of the positive test. 
Test for saponins 
0.5 g of a hydro-alcoholic extract will be dissolved in 10 ml of distilled water in a test tube. 
The test tube will be stoppered and shaken vigorously for 30 sec and allowed to stand in a 
vertical position and observed over 30 min. The formation of “honey comb” froth that 
persisted for half an hour indicates the presence of saponins. 
Test for alkaloids 
Mayer’s Test: Filtrates were treated with Mayer’s reagent (Potassium Mercuric Iodide). 
Formation of a yellow coloured precipitate indicates the presence of alkaloids.  
Test for flavonoids 
Five ml of dilute NH3 solution will be added to 3 ml aqueous filtrate of the sample followed 
by addition of 2 ml of concentrated H2SO4, and formation of yellow color indicates presence 
of flavonoids. 
Test for anthraquinones 
5.0 g of dried extract will be shaken with 10.0 ml of benzene. This will be filtered and 5.0 ml 
of 10% ammonia solution will be added to the filtrate. The mixture will be shaken and the 
presence of violet colour in the ammoniacal (lower) phase indicated the presence of free 
hydroxy anthraquinones. 
Test for tannins 
Two ml of water diluted sample will be treated with 3 drops of 10% ferric chloride and 
formation of bluish-black color indicates presence of tannins. 
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Test for terpenoids 
2ml of extract was added to 2ml of acetic anhydride and concentrated H2SO4. Formations of 
blue green rings indicate the presence of terpenoids. 
Test for triterpenes  
Extracts were treated with chloroform and filtered. The filtrates were treated with few drops 
of Conc. Sulphuric acid, shaken and allowed to stand. Appearance of golden yellow colour 
indicates the presence of triterpenes. 
Test for diterpenes 
Extracts will be dissolved in water and treated with 3-4 drops of copper acetate solution. 
Formation of emerald green colour indicates the presence of diterpenes 
Test for cardiac glycosides  
To 0.5 g of extract diluted to 5 ml in water was added 2 ml of glacial acetic acid containing 
one drop of ferric chloride solution. Then 1ml of concentrated sulphuric acid will be added. 
A brown ring at the interface indicated the presence of a deoxysugar characteristic of 
cardenolides. A violet ring may appear below the brown ring, while in the acetic acid layer a 
greenish ring may form just above the brown ring and gradually spread throughout this layer 
 Test for Steroids 
1 ml of the extract will be dissolved in 10 ml of chloroform and equal volume of 
concentrated H2SO4 will be added by sides of the test tube. The appearance of upper layer 
turning to red and sulphuric acid layer showing yellow with green fluorescence indicated the 
presence of steroids 
 
 
 
